Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.

@article{Pessa2008EfficacyAS,
  title={Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.},
  author={M{\'a}rio Guimar{\~a}es Pess{\^o}a and Brian Gazzard and Anna Huang and Carlos Eduardo Brand{\~a}o-Mello and Isabel Cassetti and Maria C{\'a}ssia Jacintho Mendes-Corr{\^e}a and Vicente Soriano and Phillip Phiri and Andrea A Hall and Helena Brett-Smith},
  journal={AIDS},
  year={2008},
  volume={22 14},
  pages={1779-87}
}
BACKGROUND Prolonged use of lamivudine in patients coinfected with HIV and hepatitis B virus (HBV) leads to an increasing risk of lamivudine resistance in both diseases. We investigated the addition of entecavir, a potent inhibitor of HBV polymerase, to lamivudine-containing highly active antiretroviral therapy (HAART) in patients who experienced rebound in HBV viremia while maintaining suppression of plasma HIV RNA less than 400 copies/ml. METHODS Sixty-eight patients were randomized to… CONTINUE READING